In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

Desmond Kwok Po Hau; Guo Yuan Zhu; Alexander Kai Man Leung; Raymond Siu Ming Wong; Gregory Yin Ming Cheng; Paul Bo San Lai; Sze Wai Tong; Fung Yi Lau; Kit Wah Chan; Wai Yeung WONG; Kim Hung Lam; Chor Hing Cheng; Filly Cheung; Chung Hin CHUI; Roberto Gambari; David W F FONG

doi:10.1016/j.phymed.2010.09.001

In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

Desmond Kwok Po Hau, Guo Yuan Zhu, Alexander Kai Man Leung, Raymond Siu Ming Wong, Gregory Yin Ming Cheng, Paul Bo San Lai, Sze Wai Tong, Fung Yi Lau, Kit Wah Chan, Wai Yeung WONG, Kim Hung Lam, Chor Hing Cheng, Filly Cheung, Chung Hin CHUI^*, Roberto Gambari, David W F FONG

^*Corresponding author for this work

Department of Chemistry

Research output: Contribution to journal › Journal article › peer-review

48 Citations (Scopus)

Abstract

We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15. mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma.

Original language	English
Pages (from-to)	11-15
Number of pages	5
Journal	Phytomedicine
Volume	18
Issue number	1
DOIs	https://doi.org/10.1016/j.phymed.2010.09.001
Publication status	Published - 15 Dec 2010

Scopus Subject Areas

Molecular Medicine
Pharmacology
Pharmaceutical Science
Drug Discovery
Complementary and alternative medicine

User-Defined Keywords

Corilagin
Hepatocellular carcinoma
Xenograft model

Access to Document

10.1016/j.phymed.2010.09.001

Cite this

Hau, D. K. P., Zhu, G. Y., Leung, A. K. M., Wong, R. S. M., Cheng, G. Y. M., Lai, P. B. S., Tong, S. W., Lau, F. Y., Chan, K. W., WONG, W. Y., Lam, K. H., Cheng, C. H., Cheung, F., CHUI, C. H., Gambari, R., & FONG, D. W. F. (2010). In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma. Phytomedicine, 18(1), 11-15. https://doi.org/10.1016/j.phymed.2010.09.001

@article{e5292d47833a454db8a291d5bf1a374d,

title = "In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma",

abstract = "We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15. mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma.",

keywords = "Corilagin, Hepatocellular carcinoma, Xenograft model",

author = "Hau, {Desmond Kwok Po} and Zhu, {Guo Yuan} and Leung, {Alexander Kai Man} and Wong, {Raymond Siu Ming} and Cheng, {Gregory Yin Ming} and Lai, {Paul Bo San} and Tong, {Sze Wai} and Lau, {Fung Yi} and Chan, {Kit Wah} and WONG, {Wai Yeung} and Lam, {Kim Hung} and Cheng, {Chor Hing} and Filly Cheung and CHUI, {Chung Hin} and Roberto Gambari and FONG, {David W F}",

year = "2010",

month = dec,

day = "15",

doi = "10.1016/j.phymed.2010.09.001",

language = "English",

volume = "18",

pages = "11--15",

journal = "Phytomedicine",

issn = "0944-7113",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

AU - Hau, Desmond Kwok Po

AU - Zhu, Guo Yuan

AU - Leung, Alexander Kai Man

AU - Wong, Raymond Siu Ming

AU - Cheng, Gregory Yin Ming

AU - Lai, Paul Bo San

AU - Tong, Sze Wai

AU - Lau, Fung Yi

AU - Chan, Kit Wah

AU - WONG, Wai Yeung

AU - Lam, Kim Hung

AU - Cheng, Chor Hing

AU - Cheung, Filly

AU - CHUI, Chung Hin

AU - Gambari, Roberto

AU - FONG, David W F

PY - 2010/12/15

Y1 - 2010/12/15

N2 - We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15. mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma.

AB - We have investigated the potential in vivo anti-tumour activity of corilagin using the Hep3B hepatocellular carcinoma cell line and an athymic nude mice xenograft model. The purity of corilagin was confirmed by high performance liquid chromatographic analysis. Corilagin was administrated intraperitoneally for a continuous period of 7 days at a concentration of 15. mg/kg of body weight per day. A significant inhibition of tumour growth was observed when treated mice are compared with control groups. Furthermore, analysis of enzymes markers of liver function, including alanine aminotransferase and asparate aminotransferase, suggested that current therapeutic dosage of corilagin did not exert adverse effect on liver. Our observations support the view that corilagin is considerably effective to retard the in vivo growth of xenografted Hep3B hepatocellular carcinoma.

KW - Corilagin

KW - Hepatocellular carcinoma

KW - Xenograft model

UR - http://www.scopus.com/inward/record.url?scp=78649775544&partnerID=8YFLogxK

U2 - 10.1016/j.phymed.2010.09.001

DO - 10.1016/j.phymed.2010.09.001

M3 - Journal article

C2 - 21036022

AN - SCOPUS:78649775544

SN - 0944-7113

VL - 18

SP - 11

EP - 15

JO - Phytomedicine

JF - Phytomedicine

IS - 1

ER -

In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

Abstract

Scopus Subject Areas

User-Defined Keywords

Access to Document

Other files and links

Fingerprint

Cite this